会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Methods and systems for increasing wireless traffic capacity in the vicinity of an event site
    • 增加事件现场附近无线通信容量的方法和系统
    • US08452335B2
    • 2013-05-28
    • US13620411
    • 2012-09-14
    • Alan GravesJeffrey FitchettBrian VezzaJohn Watkins
    • Alan GravesJeffrey FitchettBrian VezzaJohn Watkins
    • H04W40/00
    • H04W24/02H04W16/04H04W24/04
    • Network entity, method and computer-readable storage medium for use in a network that includes an arrangement of cell sites, each cell site configured to provide wireless services within a respective coverage region. The network entity may include an input configured to receive position information regarding occurrence of an event at an event site, and a processing entity configured to determine, based on the position information regarding occurrence of the event and policy information regarding the network, whether the event warrants coverage region reconfiguration and, if so, to generate a message commanding an adjustment to the coverage region of at least one cell site. An output is configured to release the message towards the at least one cell site, whereby application of the adjustment to the coverage region of the at least one cell site enables an increase in traffic to be accommodated in a vicinity of the event site.
    • 网络实体,方法和计算机可读存储介质,用于包括小区站点的布置的网络中,每个小区站点被配置为在相应覆盖区域内提供无线服务。 网络实体可以包括被配置为接收关于在事件站点处的事件的发生的位置信息的输入,以及被配置为基于关于事件的发生的位置信息和关于网络的策略信息来确定事件的事件 保证覆盖区重新配置,并且如果是,则生成指示对至少一个小区站点的覆盖区域的调整的消息。 输出被配置为向所述至少一个小区站点释放消息,由此将所述调整应用于所述至少一个小区站点的覆盖区域能够增加要容纳在所述事件站点附近的业务量。
    • 8. 发明授权
    • Modified hirudin proteins and T-cell epitopes in hirudin
    • 水蛭素修饰水蛭素蛋白和T细胞表位
    • US07425533B2
    • 2008-09-16
    • US10560918
    • 2004-06-25
    • Matthew BakerJohn Watkins
    • Matthew BakerJohn Watkins
    • C07K14/00
    • C07K14/815
    • Modified forms of hirudin having improved properties are disclosed. The modified hirudin compounds are hirudin variants comprising amino acid substitutions in the sequence of hirudin. Peptide molecules consisting of the amino acid residue sequence CILGSDGEKNQCVTGEGTPKPESHNDGDFE (SEQ ID NO: 1) or a sequence consisting of at least 9 consecutive amino acid residues of SEQ ID NO: 1 having a potential MHC class II binding activity are disclosed. The peptide has a stimulation index of >1.8 in a biological assay of cellular proliferation, in which the index is defined as the value of cellular proliferation scored following stimulation by the peptide and divided by the value of cellular proliferation scored in control cells that have not been exposed to the peptide.
    • 公开了具有改进性能的水蛭素的修饰形式。 修饰水蛭素化合物是水蛭素变体,其包含水蛭素序列中的氨基酸取代。 公开了由氨基酸残基序列CILGSDGEKNQCVTGEGTPKPESHNDGDFE(SEQ ID NO:1)组成的肽分子或由具有潜在MHC II类结合活性的SEQ ID NO:1的至少9个连续氨基酸残基组成的序列。 该肽在细胞增殖的生物测定中具有> 1.8的刺激指数,其中该指数被定义为在肽刺激后评分的细胞增殖值除以未分配的对照细胞中得到的细胞增殖的值 暴露于肽。
    • 9. 发明申请
    • Artificial proteins with reduced immunogenicity
    • 具有降低免疫原性的人造蛋白
    • US20070269435A1
    • 2007-11-22
    • US11716878
    • 2007-03-12
    • Stephen GilliesFrancis CarrJones TimGraham CarterAnila HamiltonStephen WilliamsMarian HanlonJohn WatkinsMatthew BakerJeffrey Way
    • Stephen GilliesFrancis CarrJones TimGraham CarterAnila HamiltonStephen WilliamsMarian HanlonJohn WatkinsMatthew BakerJeffrey Way
    • A61K39/395A61P35/00C07H21/00C12P21/08
    • C07K16/30C07K16/28C07K16/2863C07K2317/24C07K2317/34C07K2319/00C07K2319/30
    • The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified molecule when exposed to a species in vivo. The invention relates, above all, to novel immunoglobulin fusion proteins which essentially consist of an immunoglobulin molecule or a fragment thereof covalently fused via its C-terminus to the N-terminus of a biologically active non-immunoglobulin molecule, preferably a polypeptide or protein or a biologically active fragment thereof. In a specific embodiment, the invention relates to fusion proteins consisting of an Fc portion of an antibody which is fused as mentioned to the non-immunological target molecule which elicits biological or pharmacological efficacy. The molecules of the invention have amino acid sequences which are altered in one or more amino acid residue positions but have in principal the same biological activity as compared with the non-altered molecules. The changes are made in regions of the molecules which are identified as T-cell epitopes, which contribute to an immune reaction in a living host. Thus, the invention also relates to a novel method of making such fusion proteins by identifying said epitopes comprising calculation of T-cell epitope values for MHC Class II molecule binding sites in a peptide by computer-aided methods.
    • 本发明涉及人体修饰蛋白,优选融合蛋白,当与体内物种暴露时,与亲本非修饰分子相比具有降低的免疫原性。 本发明首先涉及新的免疫球蛋白融合蛋白,其基本上由通过其C-末端与生物活性非免疫球蛋白分子(优选多肽或蛋白质)的N末端共价融合的免疫球蛋白分子或其片段组成,或 其生物活性片段。 在一个具体的实施方案中,本发明涉及由抗体的Fc部分组成的融合蛋白,所述Fc部分如提及的非免疫靶标分子融合而引起生物学或药理学功效。 本发明的分子具有氨基酸序列,其在一个或多个氨基酸残基位置被改变,但与未改变的分子相比具有相同的生物学活性。 在被鉴定为T细胞表位的分子的区域中进行改变,其有助于在宿主中的免疫反应。 因此,本发明还涉及通过鉴定所述表位来制备此类融合蛋白的新方法,包括通过计算机辅助方法计算肽中MHC II类分子结合位点的T细胞表位值。